Percutaneous coronary revascularization in diabetics: from balloon angioplasty to drug-eluting stents

References

• Corpus RA, George PB, House JA et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated Type II diabetics patients undergoing elective percutaneous coronary intervention. J. Am. Coll. Cardiol. 43, 8–14 (2004).
   Google Scholar
• Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 100, 1134–1146 (1999).
   PubMed Web of Science ®Google Scholar
• Sobel BE, Schneider DJ. Cardiovascular complications in diabetes mellitus. Curr. Opin. Pharmacol. 5, 143–148 (2005).
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Verbeuren TJ, Van de Voorde J et al. Endothelial dysfunction in diabetes. Br. J. Pharmacol. 130, 963–974 (2000).
   PubMed Web of Science ®Google Scholar
• Luft FC. Pro-inflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr. Opin. Nephrol. Hypertens. 11, 59–66 (2002).
   PubMed Web of Science ®Google Scholar
• Golovchenko I, Goalstone ML, Watson P et al. Hyperinsulinemia enhances transcriptional activity of nuclear factor-κB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ. Res. 87, 746–752 (2000)
   PubMed Web of Science ®Google Scholar
• O’Driscoll G, Green D, Rankin J et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J. Clin. Invest. 100, 678–684 (1997).
   PubMed Web of Science ®Google Scholar
• King GL. The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in diabetes. Ann. Med. 28, 427–432 (1996).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Wautier JL et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84, 489–497 (1999).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Hori O, Brett J et al. Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler. Thromb. 14, 1521–1528 (1994).
   PubMed Web of Science ®Google Scholar
• Dresner A, Laurent D, Marcucci M et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103, 253–259 (1999).
   PubMed Web of Science ®Google Scholar
• Dichtl W, Nilsson L, Goncalves I et al. Very low-density lipoprotein activates nuclear factor-κB in endothelial cells. Circ. Res. 84, 1085–1094 (1999).
   PubMed Web of Science ®Google Scholar
• Inoguchi T, Li P, Umeda F et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49, 1939–1945 (2000).
   PubMed Web of Science ®Google Scholar
• O’Nelly WW. Multivessel balloon angioplasty should be abandoned in diabetic patient. J. Am. Coll. Cardiol. 31, 20–22 (1998).
   Google Scholar
• Oliver FJ, de la Rubia G, Feener EP et al. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J. Biol. Chem. 266, 23251–23256 (1991).
   PubMed Web of Science ®Google Scholar
• Ferri C, Pittoni V, Piccoli A et al. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J. Clin. Endocrinol. Metab. 80, 829–835 (1995).
   PubMed Web of Science ®Google Scholar
• Piatti PM, Monti LD, Conti M et al. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 45, 316–321 (1996).
   PubMed Web of Science ®Google Scholar
• Wolpert HA, Steen SN, Istfan NW et al. Insulin modulates circulating endothelin-1 levels in humans. Metabolism 42, 1027–1030 (1993).
   PubMed Web of Science ®Google Scholar
• Stout RW. Insulin and atheroma 20-yr perspective. Diabetes Care 13, 631–654 (1990).
   PubMed Web of Science ®Google Scholar
• Nishimoto Y, Miyazaki Y, Toki Y et al. Enhanced secretion of insulin plays a role in the development of atherosclerosis and restenosis of coronary arteries: elective percutaneous transluminal coronary angioplasty in patients with effort angina. J. Am. Coll. Cardiol. 32, 1624–1629 (1998).
   Google Scholar
• Osanai H, Kanayama H, Miyazaki Y, Fukushima A, Shinoda M, Ito T. Usefulness of enhanced insulin secretion during an oral glucose tolerance test as a predictor of restenosis after direct percutaneous transluminal coronary angioplasty during acute myocardial infarction in patients without diabetes mellitus. Am. J. Cardiol. 81, 698–701 (1998).
   Google Scholar
• Takagi T, Yoshida K, Akasaka T et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: a serial intravascular ultrasound study. J. Am. Coll. Cardiol. 36, 731–738 (2000).
   PubMedGoogle Scholar
• Laakso MLS. Epidemiology of macrovascular disease in diabetes. Diabetes Rev. 5, 294–315 (1997).
   Google Scholar
• Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: Diabetes in America, Second Edition.Harries MI, Cowie CC, Stern MP et al. (Eds), Government Printing Office, Washington, DC, USA, 233–257 (1995).
   Google Scholar
• Pyörolä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab. Rev. 3, 463–524 (1987).
   Google Scholar
• Barreto-Connor E. Does hyperglycaemia really cause coronary heart disease? Diabetes Care 20, 1620–1623 (1997).
   Google Scholar
• Kip KE, Faxon DP, Detre KM et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 94, 1818–1825 (1996).
   PubMed Web of Science ®Google Scholar
• Rozenman Y, Sapoznikov D, Mosseri M et al. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus a clue to the explanation of the results of the BARI study. J. Am. Coll. Cardiol. 30, 1420–1425 (1997).
   PubMed Web of Science ®Google Scholar
• Kornoski R, Mintz GS, Kent KM et al. Increase restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: a serial intravascular study. Circulation95, 1366–1369 (1997).
   Google Scholar
• Kornowski R, Mintz GS, Lansky AH et al. Paradoxical decreases in atherosclerotic plaque mass in insulin-treated diabetic patients. Am. J. Cardiol. 81, 1298–1304 (1998).
   PubMed Web of Science ®Google Scholar
• Sobel BE. Altered fibrinolysis and platelet function in the development of vascular complications of diabetes. Curr. Opin. Endocrinol. Diabetes 3, 355–360 (1996).
   Google Scholar
• Shehadeh A, Regan TJ. Cardiac consequences of diabetes mellitus. Clin. Cardiol. 18, 301–305 (1995).
   PubMed Web of Science ®Google Scholar
• Margolis JR, Kannel SW, Feinlieb M, Dawber TR, McNamara PM. Clinical features of unrecognized myocardial infarction, silent and symptomatic: 18 year follow-up: the Framingham Study. Am. J. Cardiol. 32, 1–7 (1973).
   PubMed Web of Science ®Google Scholar
• Zarich S, Waxman S, Freeman RT, Mittleman M, Hegarty P, Nesto RW. Effect of autonomic nervous system dysfunction on the circadian pattern of myocardial ischaemia in diabetes mellitus. J. Am. Coll. Cardiol. 24, 956–962 (1994).
   PubMed Web of Science ®Google Scholar
• Tomai F, Crea F, Gaspardone A et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 90, 700–705 (1994).
   PubMed Web of Science ®Google Scholar
• Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization: beyond nitric oxide and cyclic GMP. Circulation 92, 3337–3349 (1995).
   PubMed Web of Science ®Google Scholar
• Reaven GM. Role of insulin resistance in human disease. Diabetes 37, 1595–1607 (1988).
   PubMed Web of Science ®Google Scholar
• Nahser PJ, Brown RE, Oskarsson H, Winniford MD, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 91, 635–640 (1995).
   PubMedGoogle Scholar
• García MJ, McNamara PM, Gordon J, Kannel WB. Morbidity and mortality in diabetes in the Framingham population: sixteen year follow-up study. Diabetes 23, 105–111 (1974).
   Google Scholar
• Van Belle E, Périé M, Braune D et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J. Am. Coll. Cardiol. 40, 410–417 (2002).
   Google Scholar
• Stein B, Weintraub WS, Gebhart SSP et al. Influence of diabetes mellitus on early and late outcome after percutaneous coronary angioplasty. Circulation 91, 979–989 (1995).
   PubMed Web of Science ®Google Scholar
• Sarembock IJ. Stent restenosis and the use of drug-eluting stents in patients with diabetes mellitus. Curr. Diab. Rep. 4, 13–19 (2004).
   Google Scholar
• Cutlip DE, Chauhan MS, Baim DS et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J. Am. Coll. Cardiol. 40, 2082–2089 (2002).
   PubMed Web of Science ®Google Scholar
• Van belle E, Abolmaali K, Bauters C et al. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. J. Am. Coll. Cardiol. 34, 476 (1999).
   Google Scholar
• Rensing BJ, Hermans WRM, Vos J et al. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical procedural, and lesional factors related to long-term angiographic outcome. Circulation 88, 975–985 (1993).
   Google Scholar
• Elezi S, Kastrati A, Pache J et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J. Am. Coll. Cardiol. 32, 1866–1873 (1998).
   PubMed Web of Science ®Google Scholar
• Van Belle E, Ketelers R, Bauters C et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-months angiographic follow-up. Circulation 103, 1218–1224 (2001).
   Google Scholar
• Waller BF, Pinkerton CA. ‘Cutters, scoopers, shavers and scrapers’: the importance of atherectomy devices and clinical relevance of tissue removed. J. Am. Coll. Cardiol. 15, 426–428 (1990).
   PubMedGoogle Scholar
• Kimura T, Kaburagi S, Tamura T et al. Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Circulation 96, 475–483 (1997).
   PubMed Web of Science ®Google Scholar
• Glagov S, Weisenberg E, Zarins CK et al. Compensatory enlargement of atherosclerotic coronary arteries. N. Engl. J. Med. 316, 1371–1375 (1987).
   PubMed Web of Science ®Google Scholar
• Mintz GS, Popma JJ, Pichard AD et al. Arterial remodelling after coronary angioplasty. A serial intravascular ultrasound study. Circulation 94, 35–43 (1996).
   PubMed Web of Science ®Google Scholar
• Loutfi M, Mulvihill NT, Boccalatte M, Farah B, Fajadet J, Marco J. Impact of restenosis and disease progression on clinical outcome after multivessel stenting in diabetic patients. Catheter Cardiovasc. Interv. 58(4), 451–454 (2003).
   PubMed Web of Science ®Google Scholar
• The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 96, 1761–1769 (1997).
   Google Scholar
• Weintraub WS, Stein B, Kosinski A et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J. Am. Coll. Cardiol. 31, 10–19 (1998).
   PubMed Web of Science ®Google Scholar
• Gum PA, O’Keefe JH, Borkon AM Jr et al. Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients. Circulation 96(Suppl. 2), 7–10 (1997).
   Google Scholar
• Niles N, McGrath PD, Malenka D et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. J. Am. Coll. Cardiol. 37, 1008–1015 (2001).
   PubMed Web of Science ®Google Scholar
• Barsness GW, Peterson ED, Ohman EM et al. Relationship between diabetes mellitus and long-term survival after coronary K bypass and angioplasty. Circulation 96, 2551–2556 (1997).
   PubMed Web of Science ®Google Scholar
• Detre M, Guo P, Holubkov R et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 99, 633–640 (1999).
   PubMed Web of Science ®Google Scholar
• Kurbaan AS, Bowker TJ, Ilsley CD et al. Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Coronary Angioplasty versus Bypass Revascularization Investigation (CABRI). Am. J. Cardiol. 87, 947–950 (2001).
   PubMed Web of Science ®Google Scholar
• King SB III, Kosinski AS, Guyton RA, Lembo NJ, Weintraub WS. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J. Am. Coll. Cardiol. 35, 1116–1121 (2000).
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med. 331, 489–495 (1994).
   PubMed Web of Science ®Google Scholar
• Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. 331, 496–501 (1994).
   PubMed Web of Science ®Google Scholar
• Ellis SG, Savage M, Fischman D et al. Restenosis after placement of Palmaz-Schatz stents in native coronary arteries: initial results of a multicenter experience. Circulation 86, 1936–1844 (1992).
   Google Scholar
• Abizaid A, Kornowski R, Mintz GS et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J. Am. Coll. Cardiol. 32, 584–589 (1998).
   PubMed Web of Science ®Google Scholar
• Aoki J, Ong AT, Arampatzis CA et al. Comparison of three-year outcomes after coronary stenting versus coronary artery bypass grafting in patients with multivessel coronary disease, including involvement of the left anterior descending coronary artery proximally (a subanalysis of the arterial revascularization therapies study trial). Am. J. Cardiol. 94, 627–631 (2004).
   Google Scholar
• Abizaid A, Costa MA, Centemero M et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Arterial Revascularization Therapy Study (ARTS) Group. Circulation 104(5), 533–538 (2001).
   Google Scholar
• West NE, Ruygrok PN, Disco CM, Webster MW, Lindeboom WK. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 24, 109, 867–873 (2004).
   Google Scholar
• Mehran R, Dangas G, Abizaid AS et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100, 1872–1878 (1999).
   PubMed Web of Science ®Google Scholar
• Moses JW, Moussa I, Leon MB et al. Effect of catheter-based iridium-192-γ brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I randomized trial). Am. J. Cardiol. 90, 243–247 (2002).
   Google Scholar
• Gruberg L, Waksman R, Ajani AE et al. The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with diabetes mellitus. J. Am. Coll. Cardiol. 39, 1930–1936 (2002).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Wijns W, Sianos G et al. Direct stenting versus direct stenting followed by centered β-radiation with intravascular ultrasound-guided dosimetry and long-term antiplatelet treatment: results of a randomized trial: β-Radiation Investigation with Direct Stenting and Galileo in Europe (BRIDGE). J. Am. Coll. Cardiol. 44(3), 528–537 (2004).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Sianos G, van der Giessen W et al. Intracoronary β-radiation to reduce restenosis after balloon angioplasty and stenting; the β-Radiation In Europe (BRIE) study. Eur. Heart J. 23, 1351–1359 (2002).
   Google Scholar
• Tripuraneni P. Coronary artery radiation therapy for the prevention of restenosis after percutaneous coronary angioplasty II: outcomes of clinical trials. Semin. Radiat. Oncol. 12, 17–30 (2002).
   Google Scholar
• Verin V, Popowski Y, De Bruyne B et al. Endoluminal β-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The dose finding study group. N. Engl. J. Med. 344, 243–249 (2001).
   PubMedGoogle Scholar
• Höher M, Wöhrle J, Wohlfrom M et al. Intracoronary β-irradiation with a rhenium-118-filled balloon catheter. A randomized trial in patients with de novo and restenotic lesions. Circulation 107, 3022 (2003).
   Google Scholar
• Sabaté M, Pimentel G, Prieto C et al. Intracoronary brachytherapy alter stenting de novo lesions in diabetic patients. J. Am. Coll. Cardiol. 44(3), 520–527 (2004).
   PubMed Web of Science ®Google Scholar
• Marso SP, Lincoff M, Ellis S et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of the EPISTENT (Evaluation of Platelet IIb/IIIa inhibitors for STENting Trial) diabetics substudy. Circulation 100, 2477–2484 (1999).
   PubMed Web of Science ®Google Scholar
• Kleiman NS, Lincoff AM, Kereiakes D et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin. Circulation 97, 1912–1920 (1998).
   PubMed Web of Science ®Google Scholar
• Roffi M, Chef DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetics with non-ST segment-elevation acute coronary syndromes. Circulation 104, 2767–2771 (2001).
   PubMed Web of Science ®Google Scholar
• Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J. Am. Coll. Cardiol. 41, 1071–1077 (2003).
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308, 81–106 (1994).
   Google Scholar
• Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am. J. Cardiol. 90, 625–628 (2002).
   PubMed Web of Science ®Google Scholar
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The clopidogrel in unstable angina to prevent recurrent events trial investigators. N. Engl. J. Med. 345, 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281), 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl. 3), 576S–599S (2004).
   Google Scholar
• Sousa E, Costa M, Abizaid A et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents. One year angiographic and intravascular ultrasound follow-up. Circulation 104, 2007–2011 (2001).
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346, 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Muzaffer D, Kengo T et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (Randomized study with the sirolimus-eluting Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions) Trial. Circulation 106, 798–803 (2002).
   PubMed Web of Science ®Google Scholar
• Abizaid A, Costa M, Blanchard D et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur. Heart J. 25, 107–112 (2004).
   Google Scholar
• Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349, 1315–1323 (2003).
   PubMed Web of Science ®Google Scholar
• Schampaert E, Cohen EA, Schluter M et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J. Am. Coll. Cardiol. 43, 1110–1115 (2004).
   PubMed Web of Science ®Google Scholar
• Schofer J, Schluter M, Gershlick AH et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362, 1093–1099 (2003).
   PubMed Web of Science ®Google Scholar
• Moussa I, Leon M, Baim DS et al. Impact of sirolimus-eluting stent on outcome in diabetic patients. A SIRIUS (SIRolIm US-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109, 101–106 (2004).
   Google Scholar
• Sabaté M, Jiménez-Quevedo P, Angiolillo DJ et al. Sirolimus-eluting stent to prevent restenosis after stenting in diabetic patients with de novo coronary stenoses: the DIABETES (diabetes and sirolimus eluting stent) trial: 9-month angiographic results. Am. J. Cardiol. 30, 75E (2004).
   Google Scholar
• Grube E, Silber S, Hauptmann KE et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107, 38–42 (2003).
   PubMed Web of Science ®Google Scholar
• Colombo A, Drzewiecki J, Banning A et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108, 788–794 (2003).
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cox DA et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350, 221–231 (2004).
   PubMed Web of Science ®Google Scholar
• Lemos PA, Hoye A, Goedhart D et al. Clinical, angiographic and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation of Rapamycin-Eluting Stent at Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 109, 1366–1370 (2004).
   PubMed Web of Science ®Google Scholar
• Mazeika P, Prasad N, Bui S, Seidelin PH. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am. Heart J. 145, 1013–1021 (2003).
   Google Scholar
• Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY. Intensive diabetes therapy and carotid intima-media thickness in Type 1 diabetes mellitus. N. Engl. J. Med. 348, 2294–303 (2003).
   PubMed Web of Science ®Google Scholar
• Choi D, Kim SK, Choi SH. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with Type 2 diabetes. Diabetes Care 27, 2654–2660 (2004).
   PubMed Web of Science ®Google Scholar
• Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20(4), 614–620 (1997).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with Type 2 diabetes (UKPDS). UK Prospective Diabetes Study. Lancet 352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar